Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStevens, N.en
dc.contributor.authorFraser, C.en
dc.contributor.authorAlsharifi, M.en
dc.contributor.authorBrown, M.en
dc.contributor.authorDiener, K.en
dc.contributor.authorHayball, J.en
dc.identifier.citationPLoS One, 2013; 8(7):1-10en
dc.description.abstractPassive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT™ was compared to Freund’s adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT™ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund’s adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together, these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies specifically for the prevention and treatment of globally significant diseases.en
dc.description.statementofresponsibilityNatalie E. Stevens, Cara K. Fraser, Mohammed Alsharifi, Michael P. Brown, Kerrilyn R. Diener, John D. Hayballen
dc.publisherPublic Library of Scienceen
dc.rights© 2013 Stevens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectAnimals; Mice, Inbred BALB C; Sheep; Mice; Orthomyxoviridae Infections; Vaccines, Synthetic; Hemagglutinin Glycoproteins, Influenza Virus; Influenza Vaccines; Adjuvants, Immunologic; Freund's Adjuvant; Antibodies, Viral; Injections, Intraperitoneal; Injections, Subcutaneous; Dose-Response Relationship, Immunologic; Aging; Female; Influenza A Virus, H1N1 Subtype; Antibodies, Neutralizingen
dc.titleAn empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvanten
dc.title.alternativeAn empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT(TM) is functionally superior to Freund's adjuvanten
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidBrown, M. [0000-0002-5796-1932]en
dc.identifier.orcidDiener, K. [0000-0001-8417-5542]en
dc.identifier.orcidHayball, J. [0000-0002-3089-4506]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_80040.pdfPublished version2 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.